Cellectis S.A. (NASDAQ:CLLS)‘s stock had its “hold” rating reaffirmed by stock analysts at SunTrust Banks, Inc. in a research report issued to clients and investors on Friday. They presently have a $20.00 price target on the biotechnology company’s stock. SunTrust Banks, Inc.’s price objective indicates a potential downside of 30.05% from the company’s current price.

A number of other research analysts also recently weighed in on the stock. Wells Fargo & Company restated an “outperform” rating and set a $40.00 price objective (up previously from $33.00) on shares of Cellectis in a research report on Tuesday, September 5th. Zacks Investment Research raised shares of Cellectis from a “hold” rating to a “buy” rating and set a $32.00 target price for the company in a report on Wednesday, July 19th. Jefferies Group LLC set a $47.00 target price on shares of Cellectis and gave the company a “buy” rating in a report on Friday, August 25th. Nomura reduced their target price on shares of Cellectis from $49.00 to $43.00 and set a “buy” rating for the company in a report on Wednesday, September 6th. Finally, BidaskClub raised shares of Cellectis from a “strong sell” rating to a “sell” rating in a report on Wednesday, August 23rd. One analyst has rated the stock with a sell rating, two have assigned a hold rating and six have issued a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $39.00.

Shares of Cellectis (CLLS) opened at 28.59 on Friday. The stock’s market cap is $1.03 billion. Cellectis has a 52 week low of $16.09 and a 52 week high of $30.46. The stock’s 50 day moving average is $28.02 and its 200 day moving average is $28.02.

COPYRIGHT VIOLATION NOTICE: This piece was originally posted by Watch List News and is the property of of Watch List News. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of US and international copyright & trademark legislation. The correct version of this piece can be read at https://www.watchlistnews.com/cellectis-s-a-clls-earns-hold-rating-from-suntrust-banks-inc/1613969.html.

Hedge funds and other institutional investors have recently made changes to their positions in the company. ARK Investment Management LLC increased its stake in shares of Cellectis by 79.1% in the second quarter. ARK Investment Management LLC now owns 4,038 shares of the biotechnology company’s stock worth $104,000 after purchasing an additional 1,784 shares in the last quarter. Trexquant Investment LP purchased a new stake in shares of Cellectis in the first quarter worth $214,000. Williams Jones & Associates LLC purchased a new stake in shares of Cellectis in the second quarter worth $244,000. Wells Fargo & Company MN increased its stake in shares of Cellectis by 132.1% in the second quarter. Wells Fargo & Company MN now owns 9,550 shares of the biotechnology company’s stock worth $247,000 after purchasing an additional 5,435 shares in the last quarter. Finally, Eqis Capital Management Inc. increased its stake in shares of Cellectis by 27.2% in the second quarter. Eqis Capital Management Inc. now owns 10,687 shares of the biotechnology company’s stock worth $276,000 after purchasing an additional 2,287 shares in the last quarter. 14.85% of the stock is owned by hedge funds and other institutional investors.

Cellectis Company Profile

Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development and commercialization of rational genome engineering technologies. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement.

Analyst Recommendations for Cellectis (NASDAQ:CLLS)

Receive News & Ratings for Cellectis S.A. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis S.A. and related companies with Analyst Ratings Network's FREE daily email newsletter.